A citation-based method for searching scientific literature

Matthew P Goetz, James M Rae, Vera J Suman, Stephanie L Safgren, Matthew M Ames, Daniel W Visscher, Carol Reynolds, Fergus J Couch, Wilma L Lingle, David A Flockhart, Zeruesenay Desta, Edith A Perez, James N Ingle. J Clin Oncol 2005
Times Cited: 577







List of co-cited articles
775 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell'orto, Maria Olivia Biasi, Beat Thürlimann, Maria B Lyng,[...]. J Natl Cancer Inst 2012
242
37

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Werner Schroth, Matthew P Goetz, Ute Hamann, Peter A Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J Suman, Matthew M Ames,[...]. JAMA 2009
383
34

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
L Madlensky, L Natarajan, S Tchu, M Pu, J Mortimer, S W Flatt, D M Nikoloff, G Hillman, M R Fontecha, H J Lawrence,[...]. Clin Pharmacol Ther 2011
229
33

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Werner Schroth, Lydia Antoniadou, Peter Fritz, Matthias Schwab, Thomas Muerdter, Ulrich M Zanger, Wolfgang Simon, Michel Eichelbaum, Hiltrud Brauch. J Clin Oncol 2007
330
28

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Yan Jin, Zeruesenay Desta, Vered Stearns, Bryan Ward, Herbert Ho, Kyung-Hoon Lee, Todd Skaar, Anna Maria Storniolo, Lang Li, Adjei Araba,[...]. J Natl Cancer Inst 2005
677
28


Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.
P Saladores, T Mürdter, D Eccles, B Chowbay, N K Zgheib, S Winter, B Ganchev, B Eccles, S Gerty, A Tfayli,[...]. Pharmacogenomics J 2015
107
27

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
James M Rae, Suzy Drury, Daniel F Hayes, Vered Stearns, Jacklyn N Thibert, Ben P Haynes, Janine Salter, Ivana Sestak, Jack Cuzick, Mitch Dowsett. J Natl Cancer Inst 2012
187
26

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Vered Stearns, Michael D Johnson, James M Rae, Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F Hayes, Zeruesenay Desta, David A Flockhart. J Natl Cancer Inst 2003
622
24


CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
M A Province, M P Goetz, H Brauch, D A Flockhart, J M Hebert, R Whaley, V J Suman, W Schroth, S Winter, H Zembutsu,[...]. Clin Pharmacol Ther 2014
122
23

Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
T E Mürdter, W Schroth, L Bacchus-Gerybadze, S Winter, G Heinkele, W Simon, P A Fasching, T Fehm, M Eichelbaum, M Schwab,[...]. Clin Pharmacol Ther 2011
203
22

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Silvana Borges, Zeruesenay Desta, Lang Li, Todd C Skaar, Bryan A Ward, Anne Nguyen, Yan Jin, Anna Maria Storniolo, D Michele Nikoloff, Lin Wu,[...]. Clin Pharmacol Ther 2006
361
21

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
20

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Matthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W Fraser Symmans, Howard L McLeod, Mark J Ratain, Hitoshi Zembutsu,[...]. Clin Pharmacol Ther 2018
161
19

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Kazuma Kiyotani, Taisei Mushiroda, Chiyo K Imamura, Naoya Hosono, Tatsuhiko Tsunoda, Michiaki Kubo, Yusuke Tanigawara, David A Flockhart, Zeruesenay Desta, Todd C Skaar,[...]. J Clin Oncol 2010
177
17

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill,[...]. Lancet 2013
17

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Michael D Johnson, Hong Zuo, Kyung-Hoon Lee, Joseph P Trebley, James Michael Rae, Ross V Weatherman, Zeruesanay Desta, David A Flockhart, Todd C Skaar. Breast Cancer Res Treat 2004
343
17

Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Anabel Sanchez-Spitman, Vincent Dezentjé, Jesse Swen, Dirk Jan A R Moes, Stefan Böhringer, Erdogan Batman, Edith van Druten, Carolien Smorenburg, Aart van Bochove, Anneke Zeillemaker,[...]. J Clin Oncol 2019
57
29

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.
Matthew P Goetz, Vera J Suman, Tanya L Hoskin, Michael Gnant, Martin Filipits, Stephanie L Safgren, Mary Kuffel, Raimund Jakesz, Margaretha Rudas, Richard Greil,[...]. Clin Cancer Res 2013
84
19


Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Pia Wegman, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld, Sten Wingren. Breast Cancer Res 2007
209
15

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Young Chai Lim, Zeruesenay Desta, David A Flockhart, Todd C Skaar. Cancer Chemother Pharmacol 2005
211
14

The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.
L K Teh, N I Mohamed, M Z Salleh, M Rohaizak, N S Shahrun, J J Saladina, J K S Shia, H Roslan, S Sood, T S Rajoo,[...]. AAPS J 2012
51
27

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Susan A Nowell, Jiyoung Ahn, James M Rae, Joshua O Scheys, Andrew Trovato, Carol Sweeney, Stewart L MacLeod, Fred F Kadlubar, Christine B Ambrosone. Breast Cancer Res Treat 2005
230
14

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.
A Gaedigk, S D Simon, R E Pearce, L D Bradford, M J Kennedy, J S Leeder. Clin Pharmacol Ther 2008
533
14

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
V O Dezentjé, F L Opdam, H Gelderblom, J Hartigh den, T Van der Straaten, R Vree, E Maartense, C H Smorenburg, H Putter, A S Dieudonné,[...]. Breast Cancer Res Treat 2015
42
33

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
Y Xu, Y Sun, L Yao, L Shi, Y Wu, T Ouyang, J Li, T Wang, Z Fan, T Fan,[...]. Ann Oncol 2008
132
13

Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
Joanne S L Lim, Xiang A Chen, Onkar Singh, Yoon S Yap, Raymond C H Ng, Nan S Wong, Mabel Wong, Edmund J D Lee, Balram Chowbay. Br J Clin Pharmacol 2011
86
15

Clinical and biomarker predictors of side effects from tamoxifen.
Wendy Lorizio, Alan H B Wu, Mary S Beattie, Hope Rugo, Simone Tchu, Karla Kerlikowske, Elad Ziv. Breast Cancer Res Treat 2012
76
17

Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Lisette Binkhorst, Ron H J Mathijssen, Agnes Jager, Teun van Gelder. Cancer Treat Rev 2015
66
19

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Peter Fox, Rosemary L Balleine, Clara Lee, Bo Gao, Bavanthi Balakrishnar, Alexander M Menzies, Shang Heng Yeap, Sayed Sahanawaz Ali, Val Gebski, Pamela Provan,[...]. Clin Cancer Res 2016
51
23

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
William J Irvin, Christine M Walko, Karen E Weck, Joseph G Ibrahim, Wing K Chiu, E Claire Dees, Susan G Moore, Oludamilola A Olajide, Mark L Graham, Sean T Canale,[...]. J Clin Oncol 2011
131
11

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
J Gjerde, M Hauglid, H Breilid, S Lundgren, J E Varhaug, E R Kisanga, G Mellgren, V M Steen, E A Lien. Ann Oncol 2008
112
11

Pharmacogenomics of tamoxifen therapy.
Hiltrud Brauch, Thomas E Mürdter, Michel Eichelbaum, Matthias Schwab. Clin Chem 2009
101
11

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.
Werner Schroth, Stefan Winter, Thomas Mürdter, Elke Schaeffeler, Diana Eccles, Bryony Eccles, Balram Chowbay, Chiea C Khor, Arafat Tfayli, Nathalie K Zgheib,[...]. Front Pharmacol 2017
36
30

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
Matthew P Goetz, James X Sun, Vera J Suman, Grace O Silva, Charles M Perou, Yusuke Nakamura, Nancy J Cox, Philip J Stephens, Vincent A Miller, Jeffrey S Ross,[...]. J Natl Cancer Inst 2014
39
25

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Pia Wegman, Linda Vainikka, Olle Stål, Bo Nordenskjöld, Lambert Skoog, Lars-Erik Rutqvist, Sten Wingren. Breast Cancer Res 2005
171
10

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
Alastair M Thompson, Andrea Johnson, Philip Quinlan, Grantland Hillman, Marcel Fontecha, Susan E Bray, Colin A Purdie, Lee B Jordan, Roberta Ferraldeschi, Ayshe Latif,[...]. Breast Cancer Res Treat 2011
73
13

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
V C Jordan, M M Collins, L Rowsby, G Prestwich. J Endocrinol 1977
461
10

Genotype-guided tamoxifen therapy: time to pause for reflection?
Timothy L Lash, Ernst A Lien, Henrik Toft Sørensen, Stephen Hamilton-Dutoit. Lancet Oncol 2009
90
11

CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Vincent O Dezentjé, Hans Gelderblom, Ron H N Van Schaik, Judith M Vletter-Bogaartz, Tahar Van der Straaten, Judith A M Wessels, Elma Meershoek-Klein Kranenbarg, Els M Berns, Caroline Seynaeve, Hein Putter,[...]. Breast Cancer Res Treat 2014
11
90

Prediction of CYP2D6 phenotype from genotype across world populations.
Andrea Gaedigk, Katrin Sangkuhl, Michelle Whirl-Carrillo, Teri Klein, J Steven Leeder. Genet Med 2017
280
10

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Jean E Abraham, Mel J Maranian, Kristy E Driver, Radka Platte, Bolot Kalmyrzaev, Caroline Baynes, Craig Luccarini, Mitul Shah, Susan Ingle, David Greenberg,[...]. Breast Cancer Res 2010
72
12

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Solai Elango Damodaran, Suresh Chandra Pradhan, Gurusamy Umamaheswaran, Dharanipragada Kadambari, K Sathyanarayana Reddy, Chandrasekaran Adithan. Cancer Chemother Pharmacol 2012
35
25

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.
T Ramón y Cajal, A Altés, L Paré, E del Rio, C Alonso, A Barnadas, M Baiget. Breast Cancer Res Treat 2010
63
14


CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
V O Dezentjé, R H N van Schaik, J M Vletter-Bogaartz, T van der Straaten, J A M Wessels, E M-K Kranenbarg, E M Berns, C Seynaeve, H Putter, C J H van de Velde,[...]. Breast Cancer Res Treat 2013
35
25

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
N Lynn Henry, James M Rae, Lang Li, Faouzi Azzouz, Todd C Skaar, Zereunesay Desta, Matthew J Sikora, Santosh Philips, Anne T Nguyen, Anna Maria Storniolo,[...]. Breast Cancer Res Treat 2009
50
18

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Thomas P Ahern, Daniel L Hertz, Per Damkier, Bent Ejlertsen, Stephen J Hamilton-Dutoit, James M Rae, Meredith M Regan, Alastair M Thompson, Timothy L Lash, Deirdre P Cronin-Fenton. Am J Epidemiol 2017
28
32


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.